Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MRCOG Part 2 > Numbers 3 > Flashcards

Numbers 3 Flashcards

1
Q

Sensitivity and specificity of IOTA

A

95%

91%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

RMI score >200 sensitivity and specificity

A

78%

87%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk chemical peritonitis in dermoid cyst spillage

A

0.2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

% reduction in hirsutism by weight reduction 5-10%

A

40-55%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

% reduction in hair growth with Eflornithine

A

60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

% of POI who conceive

A

10-15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Number of follicles by puberty

A

0.5 million

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

% POI in Fragile X Syndrome

A

13-26%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

% POI with osteopenia

A

50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Precocious puberty incidence

A

1:5000-10,000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

% of idiopathic cause of central precocious puberty

A

74%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

% of metabolic syndrome in women with PCOS

A

33%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Risk of CHD and stroke in PCOS

Risk in metabolic syndrome

A

2x

3-6x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Risk T2DM in PCOS + metabolic syndrome

A

5x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Risk OSA in PCOS

A

30x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Incidence of congenital uterine abnormalities

A

3%
90% septate uterus
5% bicornuate
5% didelphic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

% of MRKH syndrome with renal tract abnormality

A

40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

% delayed puberty

A

3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Incidence of puerperial genital haematomas

A

1:700

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

% women who choose ELCS after previous 3rd/4th degree tear

A

25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Rate of postpartum psychosis

A

1:1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

VIN 3 progression rate

A

6.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

% VIN will show invasive cancer on excision

A

12-17%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Risk of VIN without WLE progression to cancer in 8 years

A

40-60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Risk VIN with WLE progression to cancer

A

4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Risk of leiomyosarcoma in women undergoing surgery for presumed fibroids <40yo

A

<1:500

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Risk of leiomyosarcoma in women undergoing surgery for presumed fibroids 75-79yo

A

1:100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

% vulval carcinoma that is SCC

A

90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Risk of vulval ca recurrence if disease free margin >8mm

A

0%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Risk of vulval ca recurrence if disease free margin <8mm

A

47%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Risk of fetal loss if dysgerminoma removal in pregnancy

A

25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

% that adnexal mass is not ovarian

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

% of operable vulval cancer that will have lymph node spread

A

30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Prevalence of ovarian cysts in postmenopausal women

A

5-17%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

CA125 >30 sensitivity and specificity for ovarian ca

A

81%

75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

IOTA sensitivity and specificity for ovarian cancer

A

95%

91%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

RMI sensitivity and specificity for ovarian cancer

A

78%

87%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

UK ovarian cancer complete cytoreduction %

A

<12%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Every 10% improvement in maximum cytoreduction improves survival by what %

A

5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

OC response rate in platinum resistant recurrence

A

10-20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

OC response rate in platinum refractory recurrence

A

<10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

OC response rate in platinum partially (>6/12, <12/12) sensitive recurrence

A

25-30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

OC response rate in platinum sensitive (>12/12) recurrence

A

40-75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

5yr survival Stage 1 BOT

A

95-97%

45
Q

5yr survival Stage 3 BOT

A

50-86%

46
Q

10yr survival BOT

A

70-80%

47
Q

Relapse of BOT with radical treatment

A

2.5-5.7%

48
Q

Relapse of BOT with unilateral SPO

A

0-20%

49
Q

Relapse of BOT with cystectomy

A

12-58%

50
Q

Incidence of invasive disease in recurrent BOTs

A

8-73%

51
Q

Survival % for early stage germ cell tumour

A

90%

52
Q

Survival % for advanced germ cell tumour

A

75-80%

53
Q

% of MOGCT recurrence that occurs within 1st year

A

75%

54
Q

5yr survival rate for Stage 4 epithelial ovarian cancer

A

5%

55
Q

5yr survival rate for Stage 3 epithelial ovarian cancer

A

20%

56
Q

5yr survival rate for Stage 2 epithelial ovarian cancer

A

40%

57
Q

5yr survival rate for Stage 1 epithelial ovarian cancer

A

90%

58
Q

Overall 5 yr survival for epithelial ovarian cancer

A

45%

59
Q

Sporadic FH of EOC - 1 family member - risk of EOC

A

4-5%

60
Q

Sporadic FH of EOC - 2 family members - risk of EOC

A

7%

61
Q

Hereditary EOC - 2 first degree relatives - risk of EOC

A

13-50%

62
Q

BRCA1 risk of ovarian cancer

A

35-46%

63
Q

BRCA2 risk of ovarian cancer

A

13-23%

64
Q

Lynch syndrome risk of ovarian cancer

A

3-14%

65
Q

Peutz Jeghers risk of ovarian cancer

A

20%

66
Q

% that risk reducing surgery (rrBSO) reduces breast cancer in BRCA carriers

A

30-75%

67
Q

% risk of peritoneal cancer in BRCA carriers

A

2%

68
Q

% occult malignancy in risk reducing surgery (rrBSO)

A

4-8%

69
Q

Risk of endometrial cancer with Lynch syndrome

A

40-60%

70
Q

% of STICs seen in prophylactic BSO for primary peritoneal disease

A

10-15%

71
Q

% STICs in serous ovarian carcinoma

A

48-61% (small studies)

72
Q

% that risk reducing surgery (rrBSO) can reduce ovarian/fallopian tube/peritoneal cancer in BRCA carriers

A

80%

73
Q

% risk reduction for EOC with tubal ligation/removal

A

29%

74
Q

% risk reduction of serous OC or primary peritoneal cancer with salpingectomy

A

60%

75
Q

% that ovarian cancer is hereditary

A

10-15%

76
Q

% 1st trimester miscarriage in radical trachelectomy
% 2nd trimester miscarriage
% of full term pregnancies

A

16-20% (similar to BG)
8-10%
70-75%

77
Q

Radical trachelectomy recurrence

A

4.2-5.6%

78
Q

% of conversion to laparotomy for lap treatment of endometrial cancer

A

26%

79
Q

% LN involvement in cervical ca Stage 1A1

A

1%

80
Q

% LN involvement in cervical ca Stage 1A2

A

5%

81
Q

% cervical cancer caused by HPV 16 & 18

A

70-80%

82
Q

% vulval and oropharyngeal cancer caused by HPV 16 & 18

A

40-50%

83
Q

% anal cancers caused by HPV 16 & 18

A

70-80%

84
Q

High risk HPV screen sensitivity and specificity

A

96%

99%

85
Q

% VIN caused by HPV 16

A

67.5%

86
Q

% VC caused by HPV 16

A

32.2%

87
Q

5yr survival rate stage 1 endometrial cancer

A

85-90%

88
Q

5yr survival rate stage 2 endometrial cancer

A

65%

89
Q

5yr survival rate stage 3 endometrial cancer

A

45-60%

90
Q

5yr survival rate stage 4 endometrial cancer

A

15%

91
Q

% cervical cancer that are squamous

A

70%

92
Q

Overall cervical cancer 5yr survival rate

A

68%

93
Q

Risk a TOA in postmenopausal woman

A

47%

94
Q

% CPP after 1 episode of TOA

A

12%

95
Q

% CPP after 2 episodes of TOA

A

30%

96
Q

% CPP after 3 episodes of TOA

A

67%

97
Q

% PID is polymicrobial

A

30-40%

98
Q

% PID due to chlamydia/gonorrhoea

A

25%

99
Q

Cure rate of pelvic exenteration in recurrent cervical cancer

A

30-50%

100
Q

% CIN that will regress

A

50%

101
Q

Recurrence rate of ectopic

A

18%

102
Q

Severe polyhydramnios

A

> 35cm

103
Q

Moderate polyhydramnios

A

30-34.9cm

104
Q

Mild polyhydramnios

A

25-29.9cm

105
Q

Incidence of endometrial cancer

A

28:100,000

106
Q

% of thecomas that are androgenic

A

10%

107
Q

% of abnormalities on USS that are cystic hygroma

A

35%

108
Q

% cystic hygromas associated with fetal chromosomal abnormalities

A

50%

MRCOG Part 2 (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions